Thank you for the opportunity. I just wanted to confirm on the four new molecules that have been approved in the past quarter, have they started contributing to our revenues? When can we see a full ramp-up of these molecules?
Is the end market potential for these products lucrative enough for large pharma’s? Any indication? What size could they reach? Are they expected to be blockbusters?
Yeah. Hi, sir. Thank you for the opportunity and congrats for the great results. S ir, just one question on the two commerciali zed molecules that you highlighted that have been approved now. So which therapeutic areas do they belong to and are they for biotech , or are they for big pharma? That's it. Thank you.
Okay. Okay. And, sir, just one thing. Are any of these molecules part of the Q1 numbers? Are any of the delivery part of the Q1 numbers, or are they not?